Fruquintinib

Generic Name: Fruquintinib

Brand Names: Fruzaqla

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₁₉N_₃O_₅

CAS Number: 1194506-26-7

Unique Ingredient Identifier: 49DXG3M5ZW

Background: Fruquintinib is under investigation for the treatment of NSCLC. Fruquintinib has been investigated for the treatment of ColoRectal Cancer.

Indication: 本品单药适用于既往接受过氟尿嘧啶类、奥沙利铂和伊立替康为基础的化疗，以及既往接受过或不适合接受抗血管内皮生长因子（VEGF）治疗、抗表皮生长因子受体（EGFR）治疗（RAS野生型）的转移性结直肠癌（mCRC）患者。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Fruquintinib Renal Impairment Study

Phase 1

Completed

Conditions: Renal Impairment

Interventions: Drug: Fruquintinib

First Posted Date: 2022-01-31

Last Posted Date: 2023-08-01

Lead Sponsor: Hutchmed

Target Recruit Count: 24

Registration Number: NCT05216354

Locations: 🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

Fruquintinib Hepatic Impairment Study

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: Fruquintinib

First Posted Date: 2022-01-31

Last Posted Date: 2022-10-31

Lead Sponsor: Hutchmed

Target Recruit Count: 16

Registration Number: NCT05216367

Locations: 🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

Fruquintinib in the Treatment of Soft Tissue Sarcoma

Phase 2

Conditions: Soft Tissue Sarcoma

Interventions: Drug: Fruquintinib

First Posted Date: 2021-12-02

Last Posted Date: 2022-03-02

Lead Sponsor: Fudan University

Target Recruit Count: 31

Registration Number: NCT05142631

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Phase II Study on Dose Optimization of Fruquintinib in Elderly mCRC Patients Refractory to Standard Treatment（DOFEMCRC）

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: Fruquintinib

First Posted Date: 2021-08-27

Last Posted Date: 2023-04-28

Lead Sponsor: Zhen-Yu Ding

Target Recruit Count: 29

Registration Number: NCT05025631

Locations: 🇨🇳
China West Hospital, Chengdu, Sichuan, China

The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE)

Phase 2

Conditions: Metastatic Colorectal Cancer

Interventions: Radiation: Stereotactic Ablative Radiotherapy (SABR)
Drug: Fruquintinib
Drug: Tislelizumab

First Posted Date: 2021-07-01

Last Posted Date: 2021-08-27

Lead Sponsor: Fudan University

Target Recruit Count: 68

Registration Number: NCT04948034

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors

Phase 2

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: Tislelizumab
Drug: Fruquintinib

First Posted Date: 2021-01-20

Last Posted Date: 2024-10-23

Lead Sponsor: BeiGene

Target Recruit Count: 84

Registration Number: NCT04716634

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷
National Cancer Center (NCC), Goyang-si, Gyeonggi-do, Korea, Republic of
🇨🇳
Shandong Cancer Hospital, Jinan, Shandong, China

and more 11 locations

Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal Cancer

Phase 2

Conditions: Advanced Colorectal Carcinoma

Interventions: Drug: Fruquintinib and raltitrexed
Drug: Fruquintinib

First Posted Date: 2020-10-12

Last Posted Date: 2021-10-26

Lead Sponsor: Fudan University

Target Recruit Count: 136

Registration Number: NCT04582981

Locations: 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China

A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Triple Negative Breast Cancer
Endometrial Cancer
Solid Tumor, Unspecified, Adult
Colorectal Cancer

Interventions: Drug: Fruquintinib
Drug: Tislelizumab

First Posted Date: 2020-10-08

Last Posted Date: 2024-02-09

Lead Sponsor: Hutchison Medipharma Limited

Target Recruit Count: 112

Registration Number: NCT04577963

Locations: 🇺🇸
Florida Cancer Specialists - FCS South, Port Charlotte, Florida, United States
🇺🇸
Florida Cancer Specialists - East (FCS East), West Palm Beach, Florida, United States
🇺🇸
Tennessee Oncology-Chattanooga, Chattanooga, Tennessee, United States

and more 13 locations

Fruquintinib CYP3A Inhibitor and Inducer Study

Phase 1

Completed

Conditions: Drug Drug Interaction

Interventions: Drug: Fruquintinib
Drug: Rifampin
Drug: Itraconazole

First Posted Date: 2020-09-21

Last Posted Date: 2021-06-18

Lead Sponsor: Hutchison Medipharma Limited

Target Recruit Count: 28

Registration Number: NCT04557397

Locations: 🇺🇸
WCCT, Cypress, California, United States

Real World Study of Regorafenib Versus Fruquintinib in Colorectal Cancer

Conditions: Colorectal Cancer

Interventions: Drug: Regorafenib
Drug: Fruquintinib

First Posted Date: 2020-06-16

Last Posted Date: 2020-06-16

Lead Sponsor: Peking University

Target Recruit Count: 268

Registration Number: NCT04431791

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy